ClinicalTrials.gg
CompletedNCT03282357Updated Feb 23, 2021Results posted

Evaluation of the Effectiveness and Safety of Radiesse for the Correction of Nasolabial Folds in China

An interventional study of Radiesse injectable implant (dermal filler) and Restylane injectable implant (dermal filler) in Correction of the Moderate to Severe Nasolabial Folds, sponsored by Merz North America, Inc.. Completed at 4 sites in China. Open to participants aged 22 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-02-23.

Sponsored by Merz North America, Inc. (part of Merz Pharma) · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
181
Allocation
Randomized
Ages
22 Years to 65 Years
Sex
All
01

Study summary

The objectives of this study are to evaluate the effectiveness and safety of Radiesse for the correction of nasolabial folds (NLFs).

02

Conditions studied

  • Correction of the Moderate to Severe Nasolabial Folds
03

In context

Lead sponsor

Merz North America, Inc. is the lead sponsor of 53 studies on the registry; 2 are open to participants now.

Of its 20 completed or terminated interventional studies of FDA-regulated products, 19 (95%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is 22 - 65 years of age.
  2. Has symmetrical NLFs of moderate or severe intensity (grade 3 or 4) on the WSRS as determined by the independent blinded evaluator and confirmed by the treating investigator at baseline.
  3. Both folds must have the same NLF score at baseline. 4. Has signed an .
  1. Understands and accepts the obligation not to receive any other facial procedures below the eyes during the study.
  1. Understands and accepts the obligation to present for all scheduled follow-up visits and is logistically able to meet all study requirements.
  1. Subjects of must have a negative pregnancy test result and must not be lactating at the Screening/Baseline Visit and be willing and able to use an acceptable method of (e.g. barrier methods used with a spermicidal agent, hormonal methods, IUD, surgical sterilization, abstinence) during the study. Women will be considered if one of the following conditions is documented on the medical history:
  1. with last menstrual bleeding at least 12 months prior to study; and
  2. Without a uterus and/or both ovaries.

Exclusion criteria

Exclusion Criteria:

  1. Has received surgical permanent implants, grafting, or surgery below the eyes on the face prior to injection or lower lid blepharoplasty within 6 months prior to injection.
  2. Has received within the specified (washout) period or plans to receive treatment during the study conduct with a non-permanent facial filler in any facial area below the eyes:

    1. 12 months prior to study start - hyaluronic acid [HA] or collagen
    2. 18 months prior to study start - calcium hydroxylapatite [CaHA]
  3. Has received at any time or plans to receive during the study a permanent facial filler (e.g. poly L-lactic acid [PLLA], polymethyl-methacrylate [PMMA], silicone) below the eyes.
  4. Has received within the past 6 months or plans to receive during the study facial dermal resurfacing procedures (e.g. chemical peel, dermabrasion, ablative laser resurfacing), non-invasive skin-tightening (e.g. Thermage), botulinum toxin injections, mesotherapy, or fat injections below the eyes.
  5. Has received in the past 2 weeks or plans to receive during the study any prescription wrinkle therapies (e.g. RENOVAÒ), topical , skin irritating topical preparations, or pigmenting agents (self-tanning agents) for use on the face.
  6. Has received in the past 2 months, or plans to receive medications or systemic steroids (intranasal/inhaled steroids acceptable) during the study.
  7. Has an acute inflammatory process or infection, active herpes infection, or history of chronic or recurrent infection or inflammation with the potential to interfere with the study results or increase the risk of adverse events (AEs).
  8. Has a known bleeding disorder or has received or is planning to receive anti-coagulation, anti-, or thrombolytic medications (e.g., warfarin), anti-inflammatory drugs (oral/injectable corticosteroids or NSAIDs (e.g., aspirin, ibuprofen), or other substances known to increase coagulation time (vitamins or herbal supplements, e.g., Vitamin E, garlic, gingko), from 10 days before injection to 3 days after injection.
  9. Has a history of known liver or renal function disease/disorder or has laboratory values at baseline.
  10. Has a known history of allergic/anaphylactic reactions, including to lidocaine or anesthetics of the amide type, or any of the device components.
  11. Has a history of hyper- or hypo-pigmentation in the NLFs, keloid formation, or hypertrophic scarring.
  12. Has recently lost or has the intention to lose a significant amount of weight ≥ 2 (BMI) units during the course of the study.
  13. Has any other medical condition with the potential to interfere with the study's conduct or assessments, or increase the risk of AEs.
  14. Has participated in a study in the last 30 days or is enrolled or plans to enroll in any other interfering study during participation in the study.
  15. Is an employee or direct relative of an employee of the investigational department in site or the sponsor.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Outcomes assessor)
Enrollment
181 participants (actual)

Study arms

  • Experimental
    Radiesse

    Subjects are randomized as to which of the two nasolabial folds is treated with Radiesse.

    Device: Radiesse injectable implant (dermal filler) · Device: Restylane injectable implant (dermal filler)

  • Active comparator
    Restylane

    Subjects are randomized as to which of the two nasolabial folds is treated with Restylane.

    Device: Radiesse injectable implant (dermal filler) · Device: Restylane injectable implant (dermal filler)

Interventions

  • DeviceRadiesse injectable implant (dermal filler)

    Subdermal injection.

    Also known as: Calcium hydroxylapatite particles suspected in an aqueous based gel carrier.

  • DeviceRestylane injectable implant (dermal filler)

    Subdermal injection

    Also known as: Hyaluronic acid

06

What researchers measure

Primary outcomes

  1. Percentage of NLFs With Treatment Success at Month 6

    Treatment success was defined as a greater than or equal to (\>=) 1-point improvement from baseline, as assessed by a blinded evaluator wrinkle severity rating scale (WSRS) scale. WSRS is a 5 point scale with scores as Score 1: Absent; Score 2: Mild; Score 3: Moderate; Score 4: Severe; Score 5: Extreme.

    Time frame: Month 6

Secondary outcomes

  1. Percentage of NLFs With an Improvement in the Blinded Evaluator's GAIS Score at Month 6

    The blinded evaluator rated the current cosmetic result for each NLF according to the GAIS based on live assessments during the visit compared with photographs taken at baseline before administration of treatment on each NLF. An improvement on the GAIS was classified as "improved", "much improved", or "very much improved. The GAIS is a 7-point scale, where: +3 (very much improved), +2 (much improved), +1 (improved), 0 (no change), -1 (worse), -2 (much worse), and -3 (very much worse).

    Time frame: Month 6

07

Results

Posted Feb 23, 2021

Participant flow

The study was conducted at 4 investigative sites in China.

Participant flow — Overall Study
MilestoneRadiesse and Restylane
Started181
Safety evaluation set176
Completed164
Not completed17
Withdrew: Lost to follow-up3
Withdrew: Withdrawal by subject4
Withdrew: Adverse event1
Withdrew: Other9

Outcome measures

PrimaryPercentage of NLFs With Treatment Success at Month 6

Treatment success was defined as a greater than or equal to (\>=) 1-point improvement from baseline, as assessed by a blinded evaluator wrinkle severity rating scale (WSRS) scale. WSRS is a 5 point scale with scores as Score 1: Absent; Score 2: Mild; Score 3: Moderate; Score 4: Severe; Score 5: Extreme.

Time frame:
Month 6
Reported as:
Number · Percentage of successfully treated NFLs
Percentage of NLFs With Treatment Success at Month 6
Percentage of successfully treated NFLsRadiesseRestylane
Percentage of NLFs With Treatment Success at Month 666.072.8
Statistical analysis
  • Radiesse vs Restylane · Difference in percentage: -6.8 · 95% CI -13.1 to -0.5
SecondaryPercentage of NLFs With an Improvement in the Blinded Evaluator's GAIS Score at Month 6

The blinded evaluator rated the current cosmetic result for each NLF according to the GAIS based on live assessments during the visit compared with photographs taken at baseline before administration of treatment on each NLF. An improvement on the GAIS was classified as "improved", "much improved", or "very much improved. The GAIS is a 7-point scale, where: +3 (very much improved), +2 (much improved), +1 (improved), 0 (no change), -1 (worse), -2 (much worse), and -3 (very much worse).

Time frame:
Month 6
Reported as:
Number · Percentage of NLFs
Percentage of NLFs With an Improvement in the Blinded Evaluator's GAIS Score at Month 6
Percentage of NLFsRadiesseRestylane
Percentage of NLFs With an Improvement in the Blinded Evaluator's GAIS Score at Month 678.483.3
Statistical analysis
  • Radiesse vs Restylane · Difference in percentage: -4.9 · 95% CI -9.8 to -0.3

Adverse events

Collected over Baseline up to Month 12. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Radiesse and Restylane0/176 (0%)4/176 (2.3%)56/176 (31.8%)
Most frequent serious events
Most frequent serious events
EventRadiesse and Restylane
Cervical dysplasiaReproductive system and breast disorders1/176
Endometrial thickeningReproductive system and breast disorders1/176
Uterine haemorrhageReproductive system and breast disorders1/176
Chest discomfortGeneral disorders1/176
Chest painGeneral disorders1/176
Pain in extremityMusculoskeletal and connective tissue disorders1/176
Most frequent other events
Most frequent other events
EventRadiesse and Restylane
Urinary tract infectionInfections and infestations16/176
Injection site noduleGeneral disorders14/176
Upper respiratory tract infectionInfections and infestations11/176
HyperlipidaemiaMetabolism and nutrition disorders11/176
Viral upper respiratory tract infectionInfections and infestations10/176

Baseline characteristics

The safety evaluation set (SES) was defined as all participants who received an investigational product.

Age, Continuous
Age, Continuous(years)Radiesse and Restylane
Mean45.6 ± 9.43
Sex: Female, Male
Sex: Female, Male(Participants)Radiesse and Restylane
Female170
Male6
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Radiesse and Restylane
Ethnicity — Han Chinese173
Ethnicity — Other3
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Radiesse and Restylane
Race (Asian)176
Region of Enrollment
Region of Enrollment(Participants)Radiesse and Restylane
China176
Fitzpatrick skin type
Fitzpatrick skin type(Participants)Radiesse and Restylane
Type I0
Type II0
Type III147
Type IV29
Type V0
Type VI0
Missing0
Height
Height(centimeter (cm))Radiesse and Restylane
Mean159.9 ± 5.60
Weight
Weight(kilogram (Kg))Radiesse and Restylane
Mean56.15 ± 8.434

1 further baseline measures are reported on the registry.

08

Study locations

4 sites
  • Peking University First Hospital, Merz Investigational Site #0860003
    Beijing, 100034, China
  • Southern Medical University, Nanfang Hospital, Merz Investigational Site #0860006
    Guangzhou, 510515, China
  • Zhejiang Provincial People's Hospital, Merz Investigational Site #0860005
    Hangzhou, 310014, China
  • Xiangya Hospital Central South University, Department of Aesthetic Plastic Surgery, Merz Investigational Site #'0860007
    Hunan, 410008, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2017 to primary completion in Jul 2018, 11 months.

Results were first posted in Feb 2021, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2017
First posted
Sep 13, 2017
StartActual
Jul 27, 2017
Primary completionActual
Jul 17, 2018
CompletionActual
Nov 30, 2018
Results first posted
Feb 23, 2021
Last update
Feb 23, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03282357
Responsible party
Sponsor
First posted
Sep 13, 2017
Start date
Jul 27, 2017
Primary completion
Jul 17, 2018
Completion
Nov 30, 2018
Results posted
Feb 23, 2021
Last update
Feb 23, 2021

Study contacts

Merz Medical Expert
study director · Merz North America, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion